| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.
|
J Clin Oncol
|
2012
|
3.98
|
|
2
|
Genome-wide analyses of avian sarcoma virus integration sites.
|
J Virol
|
2004
|
2.68
|
|
3
|
Cyclin D1 is a candidate oncogene in cutaneous melanoma.
|
Cancer Res
|
2002
|
1.78
|
|
4
|
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
|
Cancer Res
|
2007
|
1.76
|
|
5
|
Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.71
|
|
6
|
Hepatocyte turnover during resolution of a transient hepadnaviral infection.
|
Proc Natl Acad Sci U S A
|
2003
|
1.58
|
|
7
|
Atomic bomb survivor cataract surgery prevalence data are consistent with non-zero threshold dose--Comment on article by Nakashima et al. 2013.
|
Health Phys
|
2014
|
1.38
|
|
8
|
Proteomic analyses of pancreatic cyst fluids.
|
Pancreas
|
2009
|
1.29
|
|
9
|
Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer.
|
Cell Oncol
|
2007
|
1.24
|
|
10
|
Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver.
|
Proc Natl Acad Sci U S A
|
2003
|
1.22
|
|
11
|
Modification of integration site preferences of an HIV-1-based vector by expression of a novel synthetic protein.
|
Hum Gene Ther
|
2010
|
1.18
|
|
12
|
One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis.
|
Cancer Res
|
2008
|
1.14
|
|
13
|
Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection.
|
J Virol
|
2010
|
1.10
|
|
14
|
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.
|
PLoS One
|
2009
|
1.09
|
|
15
|
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
|
Cancer Res
|
2008
|
1.07
|
|
16
|
PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.
|
Cancer Immunol Res
|
2013
|
1.06
|
|
17
|
PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression.
|
Cancer Res
|
2005
|
1.04
|
|
18
|
5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.
|
Inflamm Bowel Dis
|
2008
|
1.03
|
|
19
|
Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression.
|
Clin Cancer Res
|
2004
|
1.01
|
|
20
|
Examining the theory of error catastrophe.
|
J Virol
|
2006
|
1.00
|
|
21
|
Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection.
|
J Virol
|
2009
|
1.00
|
|
22
|
A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.
|
Clin Trials
|
2012
|
0.99
|
|
23
|
Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis.
|
Neoplasia
|
2010
|
0.94
|
|
24
|
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
|
J Nucl Med
|
2009
|
0.93
|
|
25
|
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2009
|
0.93
|
|
26
|
Searchable high-resolution 2D gel proteome of the human colon crypt.
|
J Proteome Res
|
2007
|
0.92
|
|
27
|
Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
|
J Thorac Oncol
|
2008
|
0.92
|
|
28
|
A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
|
Oncologist
|
2014
|
0.91
|
|
29
|
Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms.
|
Cancer Res
|
2007
|
0.89
|
|
30
|
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
|
Clin Cancer Res
|
2013
|
0.88
|
|
31
|
Mechanism for CCC DNA synthesis in hepadnaviruses.
|
PLoS One
|
2009
|
0.88
|
|
32
|
p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma.
|
Cancer Gene Ther
|
2002
|
0.87
|
|
33
|
Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma.
|
Leuk Res
|
2013
|
0.86
|
|
34
|
Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver.
|
Virology
|
2013
|
0.85
|
|
35
|
Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.
|
J Virol
|
2002
|
0.85
|
|
36
|
Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.85
|
|
37
|
Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling.
|
COPD
|
2013
|
0.84
|
|
38
|
Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer.
|
Cancer Detect Prev
|
2002
|
0.83
|
|
39
|
Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
|
J Thorac Oncol
|
2007
|
0.82
|
|
40
|
Comments on "Studies of the mortality of atomic bomb survivors, report 14, 1950-2003: an overview of cancer and noncancer diseases" (Radiat Res 2012; 177:229-43).
|
Radiat Res
|
2012
|
0.78
|
|
41
|
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
|
Cancer Chemother Pharmacol
|
2002
|
0.78
|
|
42
|
Reply to S. Buti and S. Culine.
|
J Clin Oncol
|
2013
|
0.75
|
|
43
|
Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
|
Cancer
|
2003
|
0.75
|
|
44
|
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
|
Cancer Invest
|
2006
|
0.75
|